Wczytywanie kursów wyceny...
Prognoza
Średnia cena docelowa analityków wynosi 19,18 € (+96,32%). Mediana wynosi 17,77 € (+81,88%).
| Kupuj |
10 |
| Trzymaj |
2 |
| Sprzedaj |
0 |
Wiadomości Przejdź do aktualności
Immunic advances vidofludimus calcium toward Phase 3 readouts, expects data by year-end
Immunic said its Phase 3 ENSURE-1 and ENSURE-2 trials of vidofludimus calcium in relapsing MS remain on track to deliver top-line data by the end of 2026, with a potential US NDA submission in mid-2027 and a regulatory decision targeted for 2028 if results are positive. The company plans to start a Phase 3 program in progressive MS later this year following supportive Phase 2 CALLIPER analyses. In Q2, operating expenses rose to $35.3 million and net loss widened to about $34.1 million; cash and equivalents totaled $155.1 million, which management expects to fund operations into late 2027. Immunic also strengthened its leadership and board ahead of potential commercialization. » Więcej na finance.yahoo.com
Dane finansowe spółki
| (EUR) | czerwiec 2026 | |
|---|---|---|
| Przychody | 0 | - |
| Zysk brutto | 0 | - |
| Zysk netto | -29,88 mln | 31,30% |
| EBITDA | -29,79 mln | 31,13% |
Dane fundamentalne
| Wskaźnik | Wartość |
|---|---|
Kapitalizacja rynkowa | 134,85 mln € |
Liczba akcji | 13,62 mln |
Maksimum/minimum z 52 tygodni | 15,11 € - 4,39 € |
| Dywidendy | Nie |
Beta | 1,41 |
C/Z (PE Ratio) | -2,38 |
PEG (PEG Ratio) | -0,03 |
C/WK (PB Ratio) | 3,81 |
C/S (PS Ratio) | 0,00 |
Profil spółki
| Nazwa | Immunic |
| CEO | Erik Lundgren |
| Pracownicy | 100 |
